TEL-AVIV, Israel, September 2, 2015 /PRNewswire/ --
BioLight Life Sciences Investments (OTCQX: BLGTY, TASE: BOLT) (“BioLight” or the “Company”), a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announced today that presentations highlighting its IOPtiMate™ system for the treatment of glaucoma will be delivered at the Ophthalmology Futures European Forum and the XXXIII Congress of the European Society of Cataract & Refractive Surgeons (“ESCRS”), both taking place in the coming days in Barcelona, Spain.
The IOPtiMate[TM] system is based on CO2 laser technology that enables the performance of a unique filtration surgery to treat glaucoma without penetrating the inner part of the eyeball, thus allowing for substantial reductions in post-operative complications and use of eye drops compared with alternatives.
Presentation Details
“Why CLASS Should be the Gold Standard in Glaucoma Surgery”
Mr. Ronen Castro, CEO, IOPtima Ltd.
Ophthalmology Futures European Forum
Fairmont Rey Juan Carlos 1 Hotel, Barcelona
September 3, 2015 at 2:01 p.m.
“Phacoemulsification of CLASS Short-term Results”
Professor E. Wylegala, Head of the Department of Ophthalmology, OSK Hospital Katowice
Congress of the ESCRS
Fira Gran Via, Barcelona
September 5, 2015 at 8:30 a.m.
“Five Years Follow-up of CLASS in Open-angle Glaucoma Patients”
Professor N. Geffen, Department of Ophthalmology, Meir Medical Center
Congress of the ESCRS
Fira Gran Via, Barcelona
September 7, 2015 at 8:00 a.m.
“As interest in the clinical benefits of IOPtiMate[TM] grows, it is important that we continue to drive awareness and acceptance of this unique surgical system amongst researchers, regulators and clinicians through presentations at important meetings like these,” commented BioLight’s Chief Executive Officer, Suzana Nahum Zilberberg.
About BioLight Life Sciences Ltd.
BioLight invests in, manages and commercializes biomedical innovations grouped around defined medical conditions - ophthalmology and cancer diagnostics. The ophthalmic technologies include IOPtiMate™, a laser-based non-invasive surgical treatment for glaucoma; TeaRx™, a point-of-care multi-parameter diagnostic test for dry eye syndrome; Eye-D®, a controlled release drug-delivery insert platform and a new technology a drug-delivery platform for the improvement of ocular molecule transmission; and OphRx, a drug delivery technology platform for ocular uses. The cancer diagnostic technologies include proprietary tests that are designated for bladder, cervical, multiple myeloma and other cancers.
Leading key investors are Mr. Israel Makov, Chairman of Sun Pharmaceuticals, former CEO and President of Teva Pharmaceuticals and former Chairman of Given Imaging, Mr. Dilip Shanghvi, founder of Sun Pharmaceuticals, India’s largest pharmaceutical company, and Mr. Dan Oren, founder and CEO of Dexcel Pharma, the second-largest pharmaceutical manufacturer in Israel.
For more information please visit the Company’s website at http://www.bio-light.co.il.
Contacts:
BioLight
Itai Bar-Natan, CFO
Email: itai@bio-light.co.il
Tel: +972-73-2753400
SOURCE BioLight Life Sciences Investments
Help employers find you! Check out all the jobs and post your resume.
